Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer

J. L. Shenep, W. T. Hughes, P. K. Roberson, K. R. Blankenship, D. K. Baker, W. H. Meyer, F. Gigliotti, J. W. Sixbey, V. M. Santana, S. Feldman, L. Lott

Research output: Contribution to journalArticle

Abstract

We assessed two antibiotic regimens - vancomycin, ticarcillin, and amikacin, as compared with a vancomycin placebo, ticarcillin -clavulanate, and amikacin - as initial emperical therapy for febrile, neutropenic children with cancer. In a randomized, double-blind clinical trial, the planned 10-day treatment was unsuccessful in 15 percent of the vancomycin, ticarcillin, and amikacin group (n = 53), as compared with 38 percent of the group receiving ticarcillin-clavulanate and amikacin (n = 48) (P = 0.010). Of 10 episodes of breakthrough bacteremia, 9 (1 fatal) occurred in patients treated with ticarcillin-clavulanate and amikacin (P = 0.006). Each of the 10 microbial isolates was a gram-positive bacterium with similar susceptibilities to vancomycin and ticarcillin-clavulanate in vitro. Both regimens were well tolerated. None of the patients had detectable renal dysfunction, but those receiving vancomycin, ticarcillin, and amikacin were more likely to have twofold increases in serum hepatic-enzyme activity. Rashes consistent with the 'red-man' syndrome occurred in three patients upon the infusion of vancomycin and in three others who received a placebo. We conclude that the combination of vancomycin, ticarcillin, and amikacin is more effective than ticarcillin-clavulanate and amikacin as empirical antibiotic therapy in clinical settings in which gram-positive bacteremias are a serious problem.

Original languageEnglish (US)
Pages (from-to)1053-1058
Number of pages6
JournalNew England Journal of Medicine
Volume319
Issue number16
StatePublished - 1988
Externally publishedYes

Fingerprint

Ticarcillin
Clavulanic Acid
Amikacin
Vancomycin
Fever
Neoplasms
Therapeutics
Bacteremia
Placebos
Anti-Bacterial Agents
Gram-Positive Bacteria
Exanthema
Clinical Trials
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shenep, J. L., Hughes, W. T., Roberson, P. K., Blankenship, K. R., Baker, D. K., Meyer, W. H., ... Lott, L. (1988). Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. New England Journal of Medicine, 319(16), 1053-1058.

Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. / Shenep, J. L.; Hughes, W. T.; Roberson, P. K.; Blankenship, K. R.; Baker, D. K.; Meyer, W. H.; Gigliotti, F.; Sixbey, J. W.; Santana, V. M.; Feldman, S.; Lott, L.

In: New England Journal of Medicine, Vol. 319, No. 16, 1988, p. 1053-1058.

Research output: Contribution to journalArticle

Shenep, JL, Hughes, WT, Roberson, PK, Blankenship, KR, Baker, DK, Meyer, WH, Gigliotti, F, Sixbey, JW, Santana, VM, Feldman, S & Lott, L 1988, 'Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer', New England Journal of Medicine, vol. 319, no. 16, pp. 1053-1058.
Shenep, J. L. ; Hughes, W. T. ; Roberson, P. K. ; Blankenship, K. R. ; Baker, D. K. ; Meyer, W. H. ; Gigliotti, F. ; Sixbey, J. W. ; Santana, V. M. ; Feldman, S. ; Lott, L. / Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. In: New England Journal of Medicine. 1988 ; Vol. 319, No. 16. pp. 1053-1058.
@article{f1817855843a408aaa2c4a5240b56bc8,
title = "Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer",
abstract = "We assessed two antibiotic regimens - vancomycin, ticarcillin, and amikacin, as compared with a vancomycin placebo, ticarcillin -clavulanate, and amikacin - as initial emperical therapy for febrile, neutropenic children with cancer. In a randomized, double-blind clinical trial, the planned 10-day treatment was unsuccessful in 15 percent of the vancomycin, ticarcillin, and amikacin group (n = 53), as compared with 38 percent of the group receiving ticarcillin-clavulanate and amikacin (n = 48) (P = 0.010). Of 10 episodes of breakthrough bacteremia, 9 (1 fatal) occurred in patients treated with ticarcillin-clavulanate and amikacin (P = 0.006). Each of the 10 microbial isolates was a gram-positive bacterium with similar susceptibilities to vancomycin and ticarcillin-clavulanate in vitro. Both regimens were well tolerated. None of the patients had detectable renal dysfunction, but those receiving vancomycin, ticarcillin, and amikacin were more likely to have twofold increases in serum hepatic-enzyme activity. Rashes consistent with the 'red-man' syndrome occurred in three patients upon the infusion of vancomycin and in three others who received a placebo. We conclude that the combination of vancomycin, ticarcillin, and amikacin is more effective than ticarcillin-clavulanate and amikacin as empirical antibiotic therapy in clinical settings in which gram-positive bacteremias are a serious problem.",
author = "Shenep, {J. L.} and Hughes, {W. T.} and Roberson, {P. K.} and Blankenship, {K. R.} and Baker, {D. K.} and Meyer, {W. H.} and F. Gigliotti and Sixbey, {J. W.} and Santana, {V. M.} and S. Feldman and L. Lott",
year = "1988",
language = "English (US)",
volume = "319",
pages = "1053--1058",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "16",

}

TY - JOUR

T1 - Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer

AU - Shenep, J. L.

AU - Hughes, W. T.

AU - Roberson, P. K.

AU - Blankenship, K. R.

AU - Baker, D. K.

AU - Meyer, W. H.

AU - Gigliotti, F.

AU - Sixbey, J. W.

AU - Santana, V. M.

AU - Feldman, S.

AU - Lott, L.

PY - 1988

Y1 - 1988

N2 - We assessed two antibiotic regimens - vancomycin, ticarcillin, and amikacin, as compared with a vancomycin placebo, ticarcillin -clavulanate, and amikacin - as initial emperical therapy for febrile, neutropenic children with cancer. In a randomized, double-blind clinical trial, the planned 10-day treatment was unsuccessful in 15 percent of the vancomycin, ticarcillin, and amikacin group (n = 53), as compared with 38 percent of the group receiving ticarcillin-clavulanate and amikacin (n = 48) (P = 0.010). Of 10 episodes of breakthrough bacteremia, 9 (1 fatal) occurred in patients treated with ticarcillin-clavulanate and amikacin (P = 0.006). Each of the 10 microbial isolates was a gram-positive bacterium with similar susceptibilities to vancomycin and ticarcillin-clavulanate in vitro. Both regimens were well tolerated. None of the patients had detectable renal dysfunction, but those receiving vancomycin, ticarcillin, and amikacin were more likely to have twofold increases in serum hepatic-enzyme activity. Rashes consistent with the 'red-man' syndrome occurred in three patients upon the infusion of vancomycin and in three others who received a placebo. We conclude that the combination of vancomycin, ticarcillin, and amikacin is more effective than ticarcillin-clavulanate and amikacin as empirical antibiotic therapy in clinical settings in which gram-positive bacteremias are a serious problem.

AB - We assessed two antibiotic regimens - vancomycin, ticarcillin, and amikacin, as compared with a vancomycin placebo, ticarcillin -clavulanate, and amikacin - as initial emperical therapy for febrile, neutropenic children with cancer. In a randomized, double-blind clinical trial, the planned 10-day treatment was unsuccessful in 15 percent of the vancomycin, ticarcillin, and amikacin group (n = 53), as compared with 38 percent of the group receiving ticarcillin-clavulanate and amikacin (n = 48) (P = 0.010). Of 10 episodes of breakthrough bacteremia, 9 (1 fatal) occurred in patients treated with ticarcillin-clavulanate and amikacin (P = 0.006). Each of the 10 microbial isolates was a gram-positive bacterium with similar susceptibilities to vancomycin and ticarcillin-clavulanate in vitro. Both regimens were well tolerated. None of the patients had detectable renal dysfunction, but those receiving vancomycin, ticarcillin, and amikacin were more likely to have twofold increases in serum hepatic-enzyme activity. Rashes consistent with the 'red-man' syndrome occurred in three patients upon the infusion of vancomycin and in three others who received a placebo. We conclude that the combination of vancomycin, ticarcillin, and amikacin is more effective than ticarcillin-clavulanate and amikacin as empirical antibiotic therapy in clinical settings in which gram-positive bacteremias are a serious problem.

UR - http://www.scopus.com/inward/record.url?scp=0023765024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023765024&partnerID=8YFLogxK

M3 - Article

C2 - 3050517

AN - SCOPUS:0023765024

VL - 319

SP - 1053

EP - 1058

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -